Navigation Links
SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
Date:7/26/2011

ared to the $7,000 unrealized loss for the six months ended June 30, 2010.

Net loss increased 15%, or $229,000, to $1.8 million for the six months ended June 30, 2011, compared to $1.5 million for the same period in 2010. The increase in net loss reflects higher general and administrative expenses and lower revenues.  

About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented Controlled Delivery Technology (CDT) platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the advancement of the Company's nutritional business, the use of proceeds from a financing transaction, and anticipated orders of its nutritional products.  These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future.  A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the Company's ability to manage expenses, generate revenue and/or unanticipated changes in the timing, amount or terms of orders for its nutritional products.  Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
2. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
3. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
4. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
5. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
6. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
7. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
8. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
9. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
10. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
11. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 1, 2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising ... novel investigational mda-7/IL-24 tumor,suppressor agent, in patients with ... were presented today at the,annual meeting of the ... 22-patient trial, INGN 241 induced killing in all ...
... Inc.,(TSX: TLN) announced today that preliminary data from ... cancer,patients was published in abstract form as part ... Meeting in Chicago,Illinois. In the Phase I dose ... two ovarian, one duodenal and one,glioma), that had ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... ... a one and a half hour massage , ... Scottsdale, AZ (PRWEB) March 25, 2010 -- As tax day draws near, stress levels ... anxiety that the tax man bring. Enjoy $15 dollars off the retail price of an hour ...
... ... care documentation for Military Health System personnel across the Department of Defense Enterprise ... Scottsdale, AZ ... workflow solutions, has been chosen to supply clinical workflow technology to the Department of ...
... ... technology can transform the way utilities can deliver power to customers," said President & ... ... have discovered that smart grid will change every aspect of their business -- from ...
... adults, a generally healthy population, are increasingly flocking to ... treatment. Young adults remain the most likely age group ... during this pivotal transition period between adolescence and adulthood. ... care in the ED nearly twice as much ...
... The ... low in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according ... ... an unusual type of fracture of the femur, or the thigh bone, is very low in ...
... one factor, researchers say , WEDNESDAY, March 24 (HealthDay News) ... pneumonia fare better in hospitals that see more of these ... study finds. , However, once the number of these patients ... of the size of the hospital, the researchers say. , ...
Cached Medicine News:Health News:Massage Envy Offers Tax Relief for Arizona Residents 2Health News:Carefx to Provide Clinical Workflow Solutions for Military Health System 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 3Health News:Transition into adult health care is a rocky road for 20 somethings 2Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 2Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 3Health News:Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures 4Health News:Fewer Deaths in Larger, Busier Hospitals 2Health News:Fewer Deaths in Larger, Busier Hospitals 3
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
...
Medicine Products: